Synthetic Blood (SYBD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synthetic Blood (SYBD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: del clark who wrote (261)	2/16/1999 3:45:00 PM
From: Micro-Selector	Read Replies (1) of 307

IMO, this is critical turnaround point for SYBD. All three products will soon be patented in U.S. and scheduled to be researched in clinical trials during 1999. This is when most "developmental stage" biotechs listed on NASDAQ move to the $5 to $10 level. Once Phase I and Phase II clinical trials underway, they often trade in $20 to $30 range (check CLTR for example of this). If receive patent for glucose biosensor and begin clinical trials, SYBD could soon be trading near $1 and higher. A recent example of this is CELN which traded around $0.25 and moved quickly to $2 upon announcement of U.S. patents and definitive plans for clinical trials. Why is there no thread for SYBD in the under-$5.00 category? Regards, Micro

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next